Research digest / visceral-fat trials
The Tesamorelin Trials: Visceral Fat, Liver Fat, IGF-1, and Safety
What the published randomized trials measured in HIV-associated lipodystrophy — visceral and hepatic fat, fat quality, inflammatory markers — and what the safety record shows.
The short version
Most of what is known about tesamorelin comes from trials in HIV patients with lipodystrophy, where the body redistributes fat into the belly. In those trials, tesamorelin reliably shrank visceral fat (the deep belly fat) by roughly 15-18% and trimmed liver fat too, while leaving fat under the skin and overall body weight largely alone. It also raised IGF-1 (a growth signal). The catch: the benefit reverses when you stop, and because it raises a growth factor, the long-term cancer-safety data are limited. This page surveys the tesamorelin research, study by study, with every figure cited.
The pivotal visceral-fat trials
The foundation is two Phase 3 randomized controlled trials in HIV patients with abdominal fat accumulation. In the pivotal 26-week trial of 412 patients, tesamorelin 2 mg/day reduced visceral adipose tissue by 15.2% while placebo increased 5.0%; triglycerides fell 50 mg/dL (versus +9 mg/dL on placebo) and IGF-1 rose 81.0% [1]. The 52-week program (273 on tesamorelin, 137 on placebo) sustained the visceral-fat reduction at -18% versus baseline (P<0.001), with glucose changes over the year judged not clinically significant [2].
In a separate 6-month JAMA trial of 50 antiretroviral-treated adults, tesamorelin produced a -42 cm2 treatment effect on visceral fat (P=0.005) [3]. A 2026 meta-analysis of five randomized trials pooled the visceral-fat reduction at -27.7 cm2 (95% CI -38.4 to -17.1; P<0.001), with a -1.18 kg trunk-fat reduction and a +1.42 kg gain in lean mass, all without serious adverse events [15]. A pooled analysis of two Phase 3 trials found the odds of reducing visceral fat below 140 cm2 were 3.9-fold greater with tesamorelin (95% CI 2.03-7.44) [14].
Liver fat and metabolic markers
Tesamorelin's visceral-fat effect extends to the liver. In the JAMA trial, it reduced the hepatic lipid-to-water percentage by a net -2.9% (P=0.003) [3], and the 2026 meta-analysis pooled a -4.28% hepatic-fat-fraction reduction across five trials [15]. Hepatic fat is studied as an off-label research endpoint in HIV; the approved indication remains visceral-fat reduction.
The metabolic signal appears to be mediated by the visceral-fat loss itself rather than a direct growth-hormone effect. In one trial, tesamorelin reduced tissue plasminogen activator antigen and modestly raised adiponectin, and the change in inflammatory markers correlated with the degree of visceral-fat reduction — pointing to visceral fat as the mediating mechanism [12]. A separate analysis found tesamorelin improved fat quality independent of quantity, raising visceral-fat density by 6.2 Hounsfield units and subcutaneous-fat density by 4.0 HU versus placebo (both P<0.0001) [13].
Side Effects and Safety in the Research Literature
Tesamorelin's trial-reported effects centered on the expected consequences of raising endogenous growth hormone and IGF-1 — growth-hormone-class effects — with monitoring of glucose and serum IGF-1 the standard precaution [1][2]. The NIH LiverTox monograph assigns tesamorelin a likelihood score of E, unlikely to cause clinically apparent liver injury, noting no reported attributable liver-injury cases and no de novo serum-enzyme elevations in trials [5].
The genuinely reassuring data point on glucose is mechanistic: in 13 healthy men, two weeks of tesamorelin left fasting glucose (P=0.93) and insulin-stimulated glucose uptake (P=0.61) unchanged [4]. Across the 52-week HIV program, glucose changes were not clinically significant [2]. Modest glucose perturbation can nonetheless occur as a growth-hormone-class effect, so monitoring is reasonable in anyone with dysglycemia.
How Safe Is Tesamorelin in the Trials?
Within the studied HIV populations and over the trial durations, the safety profile was generally favorable: the 2026 five-trial meta-analysis reported the body-composition and metabolic benefits without serious adverse events [15], and the LiverTox class-E rating reflects an absence of attributable hepatotoxicity [5]. Insulin sensitivity was preserved in the healthy-men mechanistic study [4].
The honest boundaries are durability and duration. Visceral fat reaccumulated after discontinuation in the 52-week program, meaning the benefit was contingent on continued dosing [2]. And the trials establish safety over weeks to a year in HIV patients — not long-term safety in the general population, where no large fat-loss randomized trial has been completed.
IGF-1, Malignancy, and Long-Term Safety
Because tesamorelin raises serum IGF-1 — a growth factor — the central long-term concern is theoretical oncologic risk. The Phase 3 program showed no excess malignancy signal over 52 weeks [2], but long-term oncologic-safety data remain limited, and active malignancy is a labeled contraindication in the approved product [5].
This is the caveat the literature is most explicit about: the data are not yet long enough or large enough to characterize lifetime cancer risk, and the growth-factor mechanism is precisely why caution and a malignancy contraindication apply. It is one reason general-population, anti-aging, and performance use — all off-label — are not supported by the evidence base [5].
Who should not take tesamorelin?
Because tesamorelin raises IGF-1, active malignancy is a contraindication in the research literature, and long-term oncologic-safety data remain limited [5]. Pregnancy is also a labeled contraindication. It is additionally a WADA-prohibited substance (category S2), barred in competitive sport in and out of competition. Research-grade material is supplied for laboratory use only — not for human self-administration, and lacking the purity and potency oversight of the approved product.
Who responded in the trials
Not every patient responded equally, and the literature characterized who did. A pooled analysis of two Phase 3 trials (543 on tesamorelin, 263 on placebo) found the odds of reducing visceral fat below 140 cm2 were 3.9-fold greater with tesamorelin (95% CI 2.03-7.44), with baseline metabolic syndrome, triglycerides above 1.7 mmol/L, and white race predicting a stronger response [14]. Notably, no predictors were identifiable at three months — response had to be assessed over the longer course.
The fat-quality finding adds a dimension beyond quantity. Over 26 weeks, tesamorelin raised visceral-fat density by 6.2 Hounsfield units and subcutaneous-fat density by 4.0 HU versus placebo (both P<0.0001), a change interpreted as improved adipocyte quality independent of how much fat was lost [13]. Together these analyses sit within the same HIV-lipodystrophy visceral-fat research base — informative about the responders and the tissue, still bounded to the studied population.
How the Research Literature Reads
Read as a whole, the tesamorelin research is coherent and unusually deep for a GHRH-class compound — but it is bounded. The confirmed findings are reproducible: selective visceral-fat reduction (15.2% at 26 weeks, sustained 18% at 52 weeks, pooled -27.7 cm2 across five trials), a reliable IGF-1 rise (+81% in the pivotal trial, +181 ug/L in healthy men), a hepatic-fat reduction (net -2.9% in JAMA; -4.28% pooled), and improved fat quality [1][2][4][3][13][15].
The boundaries are equally clear and are not product reviews but literature limits: the efficacy data live in HIV-positive populations, the benefit reverses on discontinuation, the IGF-1/growth-factor concern caps the long-term safety picture, and no large general-population trial exists [2][5]. That is the genuine shape of the evidence — strong where it has been tested, explicitly silent where it has not.